Our study exemplifies the feasibility of in vivo RNA-Seq-based tumour molecular profiling from pre- and post-treatment biopsies from chemotherapy-treated patients [8] for advanced PCa to highlight the mechanisms of drug action and identify putative biomarkers of chemo-sensitivity or –resistance to (such as ORM1) and/or prognosis (such as ADAM7 and FAM72B, and the cell cycle-related genes). This evidence concerns the gene ORM1 and neoplasm.